Showing 5311-5320 of 5956 results for "".
- Analysts Give Gilead’s Remdesivir 50% Chance of Success as COVID-19 Treatmenthttps://modernod.com/news/analysts-give-gileads-remdesivir-50-chance-of-success-as-covid-19-treatment/2477362/Analysts at RBC Capital Markets suggested that it is a toss-up whether Gilead Sciences’ remdesivir will succeed in demonstrating efficacy and ultimately securing approval to treat COVID-19, citing limited dosing results, confounding data and previous disappointments in Ebola. “[The] b
- Jim Mazzo Receives the Ellis Island Medal of Honorhttps://modernod.com/news/jim-mazzo-receives-the-ellis-island-medal-of-honor/2477358/Jim Mazzo, Global President of Ophthalmic Devices with Carl Zeiss Meditec, has been chosen to receive the Ellis Island Medal of Honor in 2020. The Ellis Island Honors Society honors the importance of immigration to America’s prosperity and celebrates the contributions immigrants and their
- PRISM Vision Group Announces Agreement With The Retina Group of Washingtonhttps://modernod.com/news/prism-vision-group-announces-agreement-with-the-retina-group-of-washington-2/2477356/PRISM Vision Group announced an agreement to add its newest partner, The Retina Group of Washington (RGW), a provider of retinal and macular care in Washington, D.C., Virginia and Maryland. Terms of the deal were not disclosed. “Medicine is changing around us and over the past sever
- Nicox’s End-of-Phase 2 Meeting With the FDA Sets Stage for NCX 470 Phase 3 Program in Glaucomahttps://modernod.com/news/nicoxs-end-of-phase-2-meeting-with-the-fda-sets-stage-for-ncx-470-phase-3-program-in-glaucoma/2477350/Nicox announced that it has successfully completed an end-of-phase 2 meeting with the FDA and agreed on the design for the NCX 470 phase 3 program, as well as nonclinical and CMC plans supporting submission of a new drug application (NDA) in the U.S. NCX 470, a novel second generation nitric oxid
- Nature Gene Therapy Publishes Preclinical Data of Ocugen’s OCU400 Genetic Modifier to Treat Retinitis Pigmentosahttps://modernod.com/news/nature-gene-therapy-publishes-preclinical-data-of-ocugens-ocu400-genetic-modifier-to-treat-retinitis-pigmentosa/2477345/Ocugen announced the publication in Nature Gene Therapy of preclinical data of nuclear hormone receptor gene NR2E3 as a genetic modifier and therapeutic agent to treat multiple retinal degenerative diseases. OCU400 (NR2E3-AAV) has received two orphan drug designatio
- Prism Vision Group Announces Agreement With the Retina Group of Washingtonhttps://modernod.com/news/prism-vision-group-announces-agreement-with-the-retina-group-of-washington/2477344/Integrated eyecare services organization PRISM Vision Group announced an agreement to add The Retina Group of Washington (RGW), which provides retinal and macular care in Washington D.C., Virginia and Maryland. Terms of the deal were not disclosed. “Medicine is changing around us an
- Eyevance Pharmaceuticals launches Tobradex ST in the United Stateshttps://modernod.com/news/eyevance-pharmaceuticals-launches-tobradex-st-in-the-united-states/2477333/Eyevance Pharmaceuticals has announced the US launch of Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% following the company’s acquisition of the product in late 2019. Tobradex ST is an FDA approved, fixed-dose topical antibiotic and corticosteroid combination indicated f
- The American Optometric Association (AOA) Partners With Lyft To Offer Free Rides To Get A Comprehensive Eye Examhttps://modernod.com/news/the-american-optometric-association-aoa-partners-with-lyft-to-offer-free-rides-to-get-a-comprehensive-eye-exam/2477334/The American Optometric Association (AOA), the leading authority on quality care and an advocate for our nation’s health, representing more than 30,000 doctors of optometry, announced that it is working with Lyft, the transportation network, to offer free rides to people in select cities in
- Zeiss Concludes Acquisition of Saxonia Systems and Creates Carl Zeiss Digital Innovation in Dresden, Germanyhttps://modernod.com/news/zeiss-concludes-acquisition-of-saxonia-systems-and-creates-carl-zeiss-digital-innovation-in-dresden-germany/2477335/Zeiss has concluded its acquisition of Saxonia Systems AG, a specialist for customized software solutions. The fully acquired company will now operate as Carl Zeiss Digital Innovation. The new unit will support the Zeiss segments with their digital projects and play a leading role in terms of inn
- Graybug Vision Presents Preclinical Results for Glaucoma Drug Candidate GB-401https://modernod.com/news/graybug-vision-presents-preclinical-results-for-glaucoma-drug-candidate-gb-401/2477332/Graybug Vision presented preclinical study results for GB-401, a novel injectable depot formulation of a proprietary beta-adrenergic antagonist prodrug, as a potential sustained-delivery treatment of up to 6 months for primary open angle glaucoma (POAG), at the American Glaucoma Society annual me